Pharma Foods International Past Earnings Performance
Past criteria checks 2/6
Pharma Foods International has been growing earnings at an average annual rate of 21.6%, while the Biotechs industry saw earnings growing at 12.8% annually. Revenues have been growing at an average rate of 26.1% per year. Pharma Foods International's return on equity is 28.6%, and it has net margins of 5.4%.
Key information
21.6%
Earnings growth rate
21.9%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 26.1% |
| Return on equity | 28.6% |
| Net Margin | 5.4% |
| Last Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Pharma Foods International Co., Ltd.'s (TSE:2929) Prospects Need A Boost To Lift Shares
Oct 31
We Think Pharma Foods International's (TSE:2929) Solid Earnings Are Understated
Sep 22Is Pharma Foods International (TSE:2929) Using Too Much Debt?
Jul 23We Like Pharma Foods International's (TSE:2929) Earnings For More Than Just Statutory Profit
Mar 23Revenue & Expenses Breakdown
How Pharma Foods International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 24 | 60,601 | 3,279 | 41,409 | 1,038 |
| 31 Jul 24 | 62,147 | 3,205 | 42,561 | 978 |
| 30 Apr 24 | 63,210 | 3,869 | 43,987 | 946 |
| 31 Jan 24 | 65,081 | 4,763 | 44,956 | 909 |
| 31 Oct 23 | 67,684 | 5,187 | 46,776 | 911 |
| 31 Jul 23 | 68,572 | 3,081 | 50,757 | 840 |
| 30 Apr 23 | 68,668 | 978 | 52,449 | 890 |
| 31 Jan 23 | 66,507 | -2,849 | 54,361 | 869 |
| 31 Oct 22 | 64,609 | -3,425 | 53,051 | 827 |
| 31 Jul 22 | 60,185 | -374 | 46,211 | 766 |
| 30 Apr 22 | 57,054 | 2,004 | 41,601 | 643 |
| 31 Jan 22 | 55,180 | 5,848 | 37,015 | 622 |
| 31 Oct 21 | 50,971 | 6,499 | 34,076 | 570 |
| 31 Jul 21 | 46,752 | 3,841 | 33,486 | 522 |
| 30 Apr 21 | 37,989 | 2,437 | 27,909 | 462 |
| 31 Jan 21 | 29,294 | 1,780 | 21,643 | 419 |
| 31 Oct 20 | 20,650 | 45 | 16,179 | 457 |
| 31 Jul 20 | 15,353 | 690 | 10,900 | 437 |
| 30 Apr 20 | 13,776 | 377 | 9,931 | 419 |
| 31 Jan 20 | 11,796 | -791 | 9,624 | 400 |
| 31 Oct 19 | 11,047 | 99 | 8,272 | 323 |
| 31 Jul 19 | 10,532 | 499 | 7,601 | 317 |
| 30 Apr 19 | 9,893 | 435 | 7,294 | 302 |
| 31 Jan 19 | 9,458 | 911 | 6,448 | 298 |
| 31 Oct 18 | 8,905 | 390 | 6,450 | 287 |
| 31 Jul 18 | 7,943 | 313 | 5,743 | 274 |
| 30 Apr 18 | 7,239 | 88 | 5,434 | 264 |
| 31 Jan 18 | 6,386 | -259 | 5,084 | 239 |
| 31 Oct 17 | 5,457 | 66 | 4,033 | 235 |
| 31 Jul 17 | 4,722 | 101 | 3,366 | 241 |
| 30 Apr 17 | 4,335 | 119 | 3,009 | 251 |
| 31 Jan 17 | 3,786 | -50 | 2,691 | 283 |
| 31 Oct 16 | 3,698 | -61 | 2,488 | 319 |
| 31 Jul 16 | 3,460 | 25 | 2,192 | 313 |
Quality Earnings: 2929 has high quality earnings.
Growing Profit Margin: 2929's current net profit margins (5.4%) are lower than last year (7.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2929's earnings have grown significantly by 21.6% per year over the past 5 years.
Accelerating Growth: 2929's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2929 had negative earnings growth (-36.8%) over the past year, making it difficult to compare to the Biotechs industry average (-36.8%).
Return on Equity
High ROE: Whilst 2929's Return on Equity (28.57%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 23:19 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharma Foods International Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |